Clinical Trial Update: A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

A multi-center Phase 2 study of VEGF Trap as a single agent in acute myeloid leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• VEGF Trap (aflibercept)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Leukemia | Phase 2 | Status: WITHDRAWN